Robert Maraz
Overview
Explore the profile of Robert Maraz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lazar G, Bursics A, Farsang Z, Harsanyi L, Kosa C, Maraz R, et al.
Magy Onkol
. 2016 Sep;
60(3):194-207.
PMID: 27579720
Therapy for breast cancer today is characterised by ever more precise diagnostic methods and ever more effective oncological treatments, a trend which will certainly continue in the future. Breast preservation...
12.
Cserni G, Maraz R
Pathol Oncol Res
. 2015 Feb;
21(4):861-6.
PMID: 25648437
Whether an axillary lymph node dissection (ALND) is needed for breast cancer patients with minimal sentinel lymph node (SLN) involvement is arguable despite recent data supporting the omission of axillary...
13.
Maraz R, Boross G, Pap-Szekeres J, Marko L, Rajtar M, Ambrozay E, et al.
Breast Cancer
. 2014 May;
23(1):85-91.
PMID: 24794951
Background: Sentinel lymph node biopsy (SLNB) is a standard procedure in women with breast cancer. The risk of morbidity related to axillary lymph node dissection (ALND) is similar for men...
14.
Cserni G, Bori R, Maraz R, Leidenius M, Meretoja T, Heikkila P, et al.
Pathol Oncol Res
. 2012 Jul;
19(1):95-101.
PMID: 22798061
Although axillary lymph node dissection (ALND) has been the standard intervention in breast cancer patients with sentinel lymph node (SLN) metastasis, only a small proportion of patients benefit from this...
15.
Lazar G, Besznyak I, Boross G, Farsang Z, Gulyas G, Jakab F, et al.
Magy Onkol
. 2010 Sep;
54(3):227-34.
PMID: 20870600
No abstract available.
16.
Lazar G, Besznyak I, Boross G, Farsang Z, Gulyas G, Jakab F, et al.
Magy Seb
. 2010 Jun;
63(3):132-40.
PMID: 20570788
No abstract available.
17.
Cserni G, Bori R, Sejben I, Boross G, Maraz R, Svebis M, et al.
Orv Hetil
. 2009 Nov;
150(48):2182-8.
PMID: 19923097
Small breast cancers often require different treatment than larger ones. The frequency and predictability of further nodal involvement was evaluated in patients with positive sentinel lymph nodes and breast cancers...
18.
Coufal O, Pavlik T, Fabian P, Bori R, Boross G, Sejben I, et al.
Pathol Oncol Res
. 2009 May;
15(4):733-40.
PMID: 19440855
Several models have previously been proposed to predict the probability of non-sentinel lymph node (NSLN) metastases after a positive sentinel lymph node (SLN) biopsy in breast cancer. The aim of...
19.
Cserni G, Boross G, Maraz R, Rajtar M, Ambrozay E, Bori R, et al.
Magy Seb
. 2006 Aug;
59(3):164-72.
PMID: 16937791
Unlabelled: Sentinel node biopsy (SNB) is controversial for in situ breast cancers. We reviewed our experience with in situ and microinvasive carcinomas and surveyed the literature. Methods: SNB was performed...
20.
Maraz R, Boross G, Svebis M, Gyanti R, Vizhanyo R, Hajnal L, et al.
Magy Seb
. 2005 Nov;
58(4):225-32.
PMID: 16261868
Introduction: The neoadjuvant chemotherapy is increasingly being used in the treatment of patients with locally advanced breast cancer. We describe the hypothesis of the biological behaviour of breast cancer supporting...